Demystifying morphomolecular alterations of vasculature in interstitial lung diseases

Toyoshi Yanagihara, Kirk D. Jones

Source: Eur Respir J, 55 (3) 1902446; 10.1183/13993003.02446-2019

Journal Issue: March

Disease area: Interstitial lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Toyoshi Yanagihara, Kirk D. Jones. Demystifying morphomolecular alterations of vasculature in interstitial lung diseases. Eur Respir J, 55 (3) 1902446; 10.1183/13993003.02446-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

The genetics of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190053; 10.1183/16000617.0053-2019 Year: 2019
Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2017 - Summer school of paediatric respiratory medicine Year: 2017
Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2016 Year: 2016
Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases Source: Eur Respir J, 55 (3) 1900933; 10.1183/13993003.00933-2019 Year: 2020
Cellular interactions in the pathogenesis of interstitial lung diseases Source: Eur Respir Rev 2015; 24: 102-114 Year: 2015
The role of macrophages in interstitial lung diseases Source: Eur Respir Rev, 26 (145) 170009; 10.1183/16000617.0009-2017 Year: 2017
Clinico-radiological profile of connective tissue diseases related interstitial lung diseases Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020
Lung ultrasound in the evaluation of interstitial lung diseases in the course of connective tissue diseases Source: International Congress 2017 – Rare diseases Year: 2017
Clubbing in patients with fibrotic interstitial lung diseases Source: International Congress 2017 – ILDs: clinical problems Year: 2017
Prognostic factors of interstitial lung disease associated with primary Sjögren's syndrome Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013
Rare interstitial lung diseases Source: School Course 2014 - Interstitial lung diseases Year: 2014
B cell activating factor belonging to the TNF family might be a useful biomarker in interstitial lung diseases associated with connective tissue diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013
Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement Source: Eur Respir J 2009; 33: 882-896 Year: 2009
Suppression of epithelial abnormalities by nintedanib in induced-rheumatoid arthritis-associated interstitial lung disease mouse model Source: ERJ Open Res, 7 (4) 00345-2021; 10.1183/23120541.00345-2021 Year: 2021
Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019
Nitrofurantoin-induced interstitial lung disease Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012
Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019
Role of imaging in progressive-fibrosing interstitial lung diseases Source: Eur Respir Rev, 27 (150) 180073; 10.1183/16000617.0073-2018 Year: 2018
Bleomycin induces cellular senescence in alveolar epithelial cells Source: Eur Respir J 2003; 22: 436-443 Year: 2003